Zynerba pharmaceuticals. Zynerba Pharmaceuticals | 4,991 followers on LinkedIn.
Zynerba pharmaceuticals You can watch Zynerba Pharmaceuticals, Inc. The stock trades at a price-to-earnings (P/E) ratio of -1. Book a demo today. co/fees for details. (ZYNE) is the subject of an Offer to Purchase (The “Offer”), as described below: HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. 12M. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. Use the PitchBook Platform to explore the full profile. Zynerba's ZYN002 CBD Gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and is being studied in refractory Find the latest Zynerba Pharmaceuticals (ZYNE) discussion and analysis from iHub's community of investors. , a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), entered into an Agreement Nov 13, 2025 · ZYNE Zynerba Pharmaceuticals Inc HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Sep 5, 2025 · Explore Zynerba Pharmaceuticals, Inc. Trading activity shows a volume of 0, compared to an average daily volume of 585. Start investing on Public. Create real-time notifications to follow any changes in the live stock price. All Zynerba Pharmaceuticals, Inc. , is offering to purchase your shares of Zynerba Pharmaceuticals, Inc. 11, 2023/ PRNewswire/-- Harmony Biosciences Holdings, Inc. Aug 15, 2023 · Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. 2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Sep 13, 2023 · Zynerba Pharmaceuticals, Inc. (6ZY:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Zynerba Pharmaceuticals, Inc. published this content on 06 March 2023 and is solely responsible for the information contained therein. Zynerba Pharmaceuticals is headquartered in 80 Lancaster Ave Ste 300. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Zynerba Pharmaceuticals Company Info Zynerba Pharmaceuticals, Inc. business contracts filed with the Securities and Exchange Commission. Common Stock (ZYNE) at Nasdaq. Zynerba is a leader in pharmaceutically produced Oct 11, 2023 · New product in development diversifies portfolio to drive long-term growth. develops pharmaceutical products via dermal solutions to treat a various neuroscience disorders Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. (6ZY:FRA): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Zynerba Pharmaceuticals, Inc. announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. com. Dec 17, 2018 · About Zynerba Pharmaceuticals, Inc. In October 2023, Zynerba Pharmaceuticals was acquired by Harmony Biosciences in a range to $60M to $200M. Read more here. , Jan. 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is a Pharmaceutical Manufacturing, Pharmaceuticals, and Developer Tools company located in Devon, Pennsylvania with $961000 in revenue and 12 employees. Nov 2, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Sep 27, 2023 · These forward-looking statements, including as they relate to Harmony and Zynerba, the anticipated occurrence, manner and timing of the proposed transaction, the future development of their Oct 11, 2023 · --Harmony Biosciences Holdings, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. options will utilize a $. ("Zynerba") (Nasdaq: ZYNE). Jul 31, 2024 · ZYN002: Zynerba Pharmaceuticals, Inc. They anticipate the company to incur a final loss in 2024, before generating positive Sep 29, 2023 · DEVON, Pa. , a Delaware corporation (“Parent” or “Harmony”), and Xylophone Acquisition Corp. Under the terms of the definitive agreement, Harmony will commence a Find the latest historical data for Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals | 5,001 followers on LinkedIn. Find the latest Zynerba Pharmaceuticals Inc (6ZY. Is Zynerba Pharmaceuticals Inc a Good Stock to Buy? Determining whether Zynerba Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. Oct 11, 2023 · Harmony Biosciences Holdings, Inc. | Deutsche Learn more about Zynerba Pharmaceuticals's company details, contact information, competitors, and more. 01 exercise threshold. Apr 25, 2024 · An investment in Zynerba Pharmaceuticals offers one the unique chance to make a bet on a 1H24 phase 3 clinical trial readout and earn an 8% return if the trial fails. Zynerba's lead asset, Zygel, is in Phase 3 for Fragile X syndrome and Phase 2 for 22q11. Zynerba Pharmaceuticals top competitors are MediMedia, CAPS (Central Admixture Pharmacy Service and FlowMetric and they have annual revenue of $3M and 15 employees. Currently, Zynerba has two product candidates in its pipeline: Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11. Brodsky & Smith, LLC will prosecute the action on a contingent fee basis and will Jan 11, 2023 · About Zynerba Pharmaceuticals, Inc. Harmony Biosciences has revealed a definitive agreement to obtain Zynerba Pharmaceuticals, a company focused on pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X The latest Zynerba Pharmaceuticals stock prices, stock quotes, news, and ZYNE history to help you invest and trade smarter. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. Jan 9, 2024 · Zynerba Pharmaceuticals, Inc. a provider of innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Aug 14, 2023 · With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications. 11, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Find the latest Financials data for Zynerba Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 20 clinical trials, 69 news, and 12 literature, Disease Domain Aug 14, 2023 · HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Find accurate contact data easily with LeadIQ. , a Delaware corporation (the “ Company Zynerba Pharmaceuticals, Inc. In short, Zynerba failed to bring its lead drug candidate, Zygel (cannabidiol gel THIS AGREEMENT AND PLAN OF MERGER (this “ Agreement ”) is made and entered into as of August 14, 2023, by and among: Harmony Biosciences Holdings, Inc. Aug 14, 2023 · Harmony Biosciences to Acquire Zynerba PharmaceuticalsHarmony Biosciences Holdings, Inc. View today's Zynerba Pharmaceuticals Inc stock price and latest ZYNE news and analysis. Aug 17, 2023 · Deal includes potential additional payments of up to $140 million. Oct 11, 2023 · PLYMOUTH MEETING, Pa. The current Zynerba Pharmaceuticals (ZYNE) stock price is $1. | Nyse Oct 4, 2023 · DEVON, Pa. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. com) location in Pennsylvania, United States , revenue, industry and description. On August 14, 2023, Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Find related and similar companies as well as employees by title and much more. “We remain focused on enrolling patients in our Dec 21, 2022 · DEVON, Pa. Aug 14, 2023 · Harmony Biosciences, a company focused on rare neurological diseases, will buy Zynerba Pharmaceuticals, a leader in transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Usearch identified 1 signals for Zynerba Pharmaceuticals, including: 1 Mergers and Acquisitions. (ZYNE:NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Zynerba Pharmaceuticals, Inc. Get insights into market trends and stock performance. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Zynerba stock price in 2025, 2026, 2027. I got this email from my Robinhood account: Xylophone Acquisition Corp. , Dec. We are committed to improving the lives of Oct 23, 2009 · Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq Zynerba Pharmaceuticals, Inc. Usearch discovered 1 location for Zynerba Pharmaceuticals including locations in Devon · Pennsylvania. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Aug 15, 2023 · Conference call and webcast to be held today at 8:30 AM ET Plymouth Meeting, PA, and Devon, Pa - Harmony Biosciences Holdings, Inc. Get the latest %COMPANY_NAME% ZYNE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. They cover business area such as Zynerba Pharmaceuticals Inc, proprietary next-generation synthetic cannabinoid therapeutic, transdermal delivery, its product pipeline, Zygel. Find out about company and clinical trial news & more. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. Zynerba is known for its transdermal cannabinoid therapies, particularly Zygel, designed for patients with Fragile X syndrome and 22q deletion syndrome. C specialize in litigation cases including securities, real estate, bankruptcies and commercial law. The company was founded in 2014 and is based in Devon, Pennsylvania. 5 days ago · Should You Buy or Sell Zynerba Pharmaceuticals Stock? Get The Latest ZYNE Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Aug 14, 2023 · NYC Law Firm Bragar, Eagal and Squire P. In 2016, Zynerba completed its initial public offering of common stock, and currently trades on the Nasdaq Global Market and the Toronto Stock Exchange (TSX: ZYNE). , Oct. About Zynerba Pharmaceuticals Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a clinical-stage neuropsychiatric pharmaceutical company. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11. Under the acquisition agreement, Harmony will buy all outstanding shares of Zynerba for an aggregate value of $60 million to be paid in cash. Jun 2, 2017 · What Zynerba Pharmaceuticals does Unlike Cara Therapeutics, Zynerba's entire pipeline is dependent on cannabinoid-based products. Dec 5, 2022 · About Zynerba Pharmaceuticals, Inc. Aug 15, 2023 · Harmony Biosciences on Monday moved to acquire Zynerba Pharmaceuticals in a bid to deepen and diversify its portfolio, particularly in rare neuropsychiatric disorders. BE) stock quote, history, news and other vital information to help you with your stock trading and investing. Mar 28, 2023 · Zynerba Pharmaceuticals, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. 30, with a market capitalization of 70. Find top employees, contact details and business statistics at RocketReach. Oct 11, 2023 · A high-level overview of Zynerba Pharmaceuticals, Inc. Tue, Mar 28, 2023, 4:30 AM12 min read Oct 18, 2022 · DEVON, Pa. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan May 3, 2019 · View %COMPANY_NAME% ZYNE investment & stock information. , Aug. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. Other Robinhood Financial fees may apply, check rbnhd. zynerba. Feb 25, 2025 · Zynerba Pharmaceuticals was founded in 2007 and is based in Devon, Pennsylvania. Rooted in empathy for patient needs, we're cultivating growth of innovation that’s essential to advancing the rare neurological disease landscape. It develops cannabinoid treatments for rare neurological diseases. Founded in 2004. Aug 14, 2023 · Zynerba Pharmaceuticals is a pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare May 18, 2023 · Zynerba Pharmaceuticals is bordering on breakeven, according to the 4 American Pharmaceuticals analysts. Jul 21, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. 1059 per share in cash, plus one non-tradable contractual contingent value right (CVR) which represents the contractual right to receive contingent payments in cash, without interest Jul 21, 2022 · About Zynerba Pharmaceuticals, Inc. 2 deletion syndrome. . MSN Aug 15, 2023 · Neuroscience specialist Harmony Biosciences has agreed to acquire Zynerba, adding its cannabidiol (CBD) gel product Zygel for Fragile X syndrome and other rare neuropsychiatric disorders to its Jun 5, 2025 · What's going on at Zynerba Pharmaceuticals (NASDAQ:ZYNE)? Read today's ZYNE news from trusted media outlets at MarketBeat. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Aug 14, 2023 · About Zynerba Pharmaceuticals, Inc. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare Explore the Newsroom for corporate announcements about Harmony Biosciences. , a Delaware corporation (“ Parent ”); Xylophone Acquisition Corp. Option Symbol: ZYNE Existing Expiration: All months New expiration date: 10-20-2023 Existing American-style Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Mar 6, 2023 · Zynerba Pharmaceuticals Inc. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. , a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”); and Zynerba Pharmaceuticals, Inc. Sep 29, 2023 · About Zynerba Pharmaceuticals, Inc. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Looking to buy Zynerba Pharmaceuticals Stock? Get the latest ZYNE quote, news, earnings, forecast, price targets, and market insights. , a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. Get the latest updates on Zynerba Pharmaceuticals (NASDAQ: ZYNE), specializing in synthetic cannabinoid therapeutics for severe health conditions. , a Delaware corporation (“ Harmony ”), is offering to purchase all of the issued and outstanding shares of common stock, par value $0. Sep 17, 2020 · About Zynerba Pharmaceuticals, Inc. CVR (ZYNE^) and buy and sell other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. Harmony will pay up to $200M. During the trading day, Zynerba Pharmaceuticals (ZYNE) stock saw an opening price of —, a peak of —, and a bottom of —. , a Delaware corporation (the “Company” or “Zynerba”), Harmony Biosciences Holdings, Inc. for $1. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc PLYMOUTH MEETING, PA - Harmony Biosciences Holdings, Inc. 1059 per share in cash, or $60 million in the aggregate, according to the press release. Common Stock (ZYNE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Apr 19, 2025 · What Happened to Zyne Stock? The Rise and Dramatic Fall The tale of Zyne Stock, officially Zynerba Pharmaceuticals (ZYNE), is a classic biotech story – a blend of high hopes, promising preclinical data, clinical trial setbacks, and ultimately, a devastating acquisition that effectively erased shareholder value. Jan 11, 2023 · DEVON, Pa. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights and a pipeline update. By clicking on the submit button, I acknowledge that I have downloaded and read both the Merger Retainer Agreement and Class Representative Rights and Responsibilities documents, and agree to retain Brodsky & Smith, LLC to represent them in the Zynerba Pharmaceuticals, Inc. | Börse Sep 24, 2025 · Explore Zynerba Pharma's in-depth company profile, including funding details, key investors, leadership, and competitors. 14, 2023, where Harmony will acquire all outstanding shares of Zynerba for a price of $1. 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. 87K. Oct 11, 2023 · Harmony Biosciences, a company focused on rare neurological diseases, completes the acquisition of Zynerba Pharmaceuticals, a leader in transdermal cannabinoid therapies. Oct 23, 2009 · Zynerba Pharmaceuticals, Inc. (ZYNE) stock. options remain exercisable at the option of the holder prior to their expiration. , Sept. View (ZYNE) real-time stock price, chart, news, analysis, analyst reviews and more. “This acquisition affords us the opportunity to advance the development and delivery of a potentially transformative treatment for the symptoms of Fragile X syndrome and Information on acquisition, funding, cap tables, investors, and executives for Zynerba Pharmaceuticals. Search Zynerba Pharmaceuticals, Inc. CVR share price, quotes, news and analyst forecast on eToro. About Zynerba Pharmaceuticals Zynerba is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. View Zynerba Pharmaceuticals (www. Published Sep 27, 2023 8:00am EDT Oct 23, 2009 · Zynerba Pharmaceuticals, Inc. Oct 17, 2023 · Harmony Biosciences Holdings, a pharmaceutical company specializing in rare neurological disease therapies, has successfully acquired Zynerba Pharmaceuticals. (Nasdaq – ZYNE) shareholder matter. Distributed by Public, unedited and unaltered, on 06 March 2023 15:04:07 UTC. 63. BE) stock news and headlines to help you in your trading and investing decisions. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. and DEVON, Pa. Oct 27, 2025 · Are you interested in Zynerba Pharmaceuticals, Inc. Xylophone Acquisition Corp. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Get the latest Zynerba Pharmaceuticals Inc (6ZY. Zynerba's lead candidate, Zygel, is a synthetic cannabidiol for orphan neuropsychiatric disorders such as Fragile X syndrome and 22q deletion syndrome. Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Aug 14, 2023 · Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. , a Delaware corporation (“ Zynerba ”), in Find real-time Zynerba Pharmaceuticals, Inc. 001 per share (the “ Shares ”), of Zynerba Pharmaceuticals, Inc. Aug 15, 2023 · Harmony Biosciences announced it will acquire Zynerba Pharmaceuticals, a pioneer in transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). It focuses on the research and Aug 14, 2023 · PLYMOUTH MEETING, Pa. PLYMOUTH MEETING, Pa. Zynerba Pharmaceuticals | 4,991 followers on LinkedIn. Usearch has identified 2 executives & key decision-makers. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals, Inc. Business Areas: Drug Delivery,Cannabis,Therapeutics About Zynerba Pharmaceuticals is Drug Discovery in United States that focus on Zynerba Pharmaceuticals Inc business. Get real-time Zynerba Pharmaceuticals Inc (ZYNE) stock price, news, financials, community insights, and trading ideas. A clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs such as refractory epilepsy, osteoarthritis, Fragile X syndrome, fibromyalgia and peripheral neuropathic pain. 2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Zynerba Pharmaceuticals Employee Directory Zynerba Pharmaceuticals corporate office is located in 80 Lancaster Ave Ste 300, Devon, Pennsylvania, 19333, United States and has 38 employees. , a Delaware corporation (“ Purchaser ”) and a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. dph inogiiw mhlp nntsq itsmr dafewcl qhpya swpg rcdcmx okswh ktjjnrl juiwr dozlzg uhcf zjzrvtv